Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Lan Lu

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Journal of Antimicrobial Chemotherapy|February 4, 2012
Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in TaiwanChung-Chih Lai, Chien-Ching Hung, Mao-Yuan Chen, et al.
Cell|August 19, 2014
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized miceAriel Halper-Stromberg, Ching-Lan Lu, Florian Klein, et al.
Journal of Virology|February 1, 2019
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment InterruptionLine K Vibholm, Julio C C Lorenzi, Joy A Pai, et al.
The Journal of Experimental Medicine|August 4, 2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Yehuda Z Cohen, Julio C C Lorenzi, Lisa Krassnig, et al.
Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Journal of Antimicrobial Chemotherapy|February 4, 2012
Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in TaiwanChung-Chih Lai, Chien-Ching Hung, Mao-Yuan Chen, et al.
Cell|August 19, 2014
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized miceAriel Halper-Stromberg, Ching-Lan Lu, Florian Klein, et al.
Journal of Virology|February 1, 2019
Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment InterruptionLine K Vibholm, Julio C C Lorenzi, Joy A Pai, et al.
The Journal of Experimental Medicine|August 4, 2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Yehuda Z Cohen, Julio C C Lorenzi, Lisa Krassnig, et al.
Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
Pageof 3